Table 1 General features of the eligible studies
Studies | Country/Region | Year | Study type/Patients enrollment period | Multicenter | Study patients | Stent | Study quality |
|---|---|---|---|---|---|---|---|
Liu et al | Japan | 2013 | Respective cohort study/ 2005–2009 | NO | Successful CTO PCI: DM/ Non-DM:51/102 | DES:62.9%, BMS:31.4% | 8 |
Claessen | United states, South Korea, and Italy | 2011 | Prospective cohort study/ 1998–2007 | YES | 1.Successful CTO PCI: DM/ Non-DM: 202/528 2. DM (395) Failed/successful PCI: 120/275 Non-DM (1347) Failed/successful PCI: 432/915 | 1.DES:100% 2.DES: more than 60% | 8 |
Sohrabi et al | Iran | 2011 | Prospective cohort study/ 2009–2011 | NO | Successful CTO PCI: DM/ Non-DM:34/129 | DES:NA, BMS: NA | 8 |
Ruiz-Garcia | Spain and Portugal | 2015 | RCT/NA | YES | Successful CTO PCI: DM/Non-DM:75/132 | DES: 100% | 4 |
Rha et al | Korea | 2015 | Respective cohort study/ 2007–2009 | YES | Successful CTO PCI: DM/Non-DM: 920/920 | DES:100% | 8 |
Yang et al | China | 2020 | Prospective cohort study/ 2016–2018 | NO | Successful CTO PCI: DM/Non-DM:198/335 | DES:100% | 8 |
Sanguineti et al | France | 2017 | Prospective cohort study/ 2004–2012 | NO | DM(362): Failed /successful PCI: 103/259 Non-DM (958): Failed /successful PCI: 227/731 | DES: more than 90% | 9 |
Tsai et al | Taiwan | 2020 | Respective cohort study/ 2005–2015 | NO | DM (313) Failed/successful PCI: 48/265 Non-DM(426) Failed/successful PCI: 72/354 | NA | 8 |
Guo et al | China | 2020 | Respective cohort study/ 2007–2018 | NO | DM (755) PCI / initial MT: 249/506 Non-DM (1260) PCI / initial MT: 469/791 | Almost all DES | 8 |
Yan et al | China | 2019 | Respective cohort study/ 2007–2017 | NO | DM (733) PCI/CTO-MT: 309/424 | Almost all DES | 7 |
Flores-Umanzor et al | Spain | 2020 | Prospective cohort study/ 2010–2014 | NO | DM (402) PCI/CTO-MT: 76/326 | DES:100% | 8 |